StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Adempas / Verquvo (sGC stimulator alliance with Bayer by Year

Adempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. reported growth YoY (%) (%)

Merck Adempas / Verquvo (sGC stimulator alliance with Bayer: 8.0% in FY2025, down 3.0 pts from a year earlier.

Latest, FY2025
8.0%
Period ended Dec 31, 2025
Change on a year earlier
-3.0 pts
11.0% in FY2024
History
4 years
Since FY2021
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Alliance Revenue - Adempas/Verquvo (5) | 470 | 415 | 13 | 421 | 388 | 8 | 49 | 27 | 81”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdempas / Verquvo (sGC stimulator alliance with Bayer — total Merck revenue) — U.S. reported growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 20258.0%-3.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 202411.0%+5.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2023Dec 31, 20236.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 202121.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗

Cite this data

StockData. (2026). Merck Adempas / Verquvo (sGC stimulator alliance with Bayer (%), annual FY2021–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-adempas-verquvo-us-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.